A Phase 1 Study of Mosliciguat in Healthy, Adult Males

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 10, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

May 31, 2026

Conditions

Healthy Volunteer

Interventions

DRUG

Mosliciguat

Dose level for inhalation

DRUG

14C mosliciguat

Dose level

DEVICE

Dry Powder Inhaler

Dry powder inhaler for mosliciguat

Trial Locations (1)

Pharmaron, Baltimore

All Listed Sponsors

lead

Pulmovant, Inc.

INDUSTRY

NCT07185321 - A Phase 1 Study of Mosliciguat in Healthy, Adult Males | Biotech Hunter | Biotech Hunter